Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. The Lancet Oncology, 2019, 20(2): 282-296. [2] Qin S, Shao G, Bai Y, et al. Chinese population analysis in REACH-2: A phase III trial of ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma and elevated baseline alpha-fetoprotein following first-line sorafenib. 2021 Chinese Society of Clinical Oncology (CSCO) annual meeting. [3] Sung H, Ferlay J, Siegel R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2021, 71(3): 209-249. [4] Tangkijvanich P et al. J Clin Gastroenterol 2000, 31(4):302-8 [5] 国家卫健委《原发性肝癌诊疗指南(2022年版)》 [6] Lu D, et al. Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. J Biol Chem. 2003; 278: 43496–43507. [7] Clarke JM, et al. Targeted inhibition of VEGF receptor 2: an update on ramucirumab. Expert Opin Biol Ther. 2013; 13: 1187–1196. lg...